OncoMatch/Lung Cancer — Small Cell (SCLC)/BRCA1

Lung Cancer — Small Cell (SCLC)BRCA1 Clinical Trials

BRCA1 alterations occur in approximately 5–8% of SCLC and may confer sensitivity to PARP inhibition given SCLC's inherently high genomic instability and reliance on homologous recombination repair. Olaparib and veliparib have been explored in biomarker-enriched SCLC cohorts. Trials investigate PARP inhibitor combinations with platinum chemotherapy or immunotherapy specifically in BRCA1/2-altered or HRD-positive SCLC.